Starling Oncology, Inc. (STLN) Stock Analysis & Investment Frameworks
Starling Oncology, Inc. (STLN) stock analysis on Invetso. Review Starling Oncology, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Starling Oncology, Inc. Company Overview
- Exchange: NASDAQ
- Sector: Healthcare
- Industry: Medical - Care Facilities
- Country: US
Starling Oncology, Inc. Key Financial Metrics
- Market Cap: $679.38M
- Revenue: $502.73M
- ROE: 209.81%
- ROIC: -28.82%
- Dividend Yield: N/A
About Starling Oncology, Inc.
Starling Oncology, Inc., formerly The Oncology Institute, is a value-based oncology company advancing cancer care in the community setting. Founded in 2007, the company offers cutting-edge, evidence-based cancer treatments, including clinical trials and transfusions, to a large patient population. It operates as an integrated oncology platform serving patients, providers, and health plans across multiple markets with a focus on delivering high-quality, patient-centered care.